Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lysine (K)-specific methyltransferase 2A | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Neospora caninum | Multidomain chromatinic protein with the following architecture: 3x PHD-bromo-3xPHD-SET domain and associated cysteine cluster a | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Schistosoma japonicum | ko:K09188 myeloid/lymphoid or mixed-lineage leukemia protein 3, putative | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0939 | 0.0754 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.2139 | 0.2052 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0525 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.2139 | 0.1704 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0035 | 0.4393 | 0.4842 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.2139 | 0.1704 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.2139 | 0.372 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.2139 | 0.1681 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0525 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.2139 | 0.372 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.2139 | 0.2052 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0525 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.2139 | 0.372 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.2139 | 0.372 |
Onchocerca volvulus | 0.0035 | 0.4393 | 0.5 | |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0066 | 0.8867 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.2139 | 0.1681 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0525 | 1 |
Trichomonas vaginalis | helicase, putative | 0.0008 | 0.0525 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.2139 | 0.2052 |
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0939 | 0.0754 |
Brugia malayi | CXXC zinc finger family protein | 0.0035 | 0.4393 | 0.4856 |
Echinococcus multilocularis | cpg binding protein | 0.0037 | 0.4678 | 1 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.2139 | 0.372 |
Schistosoma mansoni | cpg binding protein | 0.0035 | 0.4393 | 0.4331 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4678 | 0.4619 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.8073 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.2139 | 0.2052 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0525 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4678 | 0.4619 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0009 | 0.0634 | 0.0531 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.8073 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0525 | 1 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.2139 | 0.372 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0525 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.8073 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0525 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5326 | 0.5275 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5326 | 0.615 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5326 | 0.616 |
Echinococcus granulosus | cpg binding protein | 0.0037 | 0.4678 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.8073 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0525 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.